Two healthcare stocks are shining among the healthcare sector ASX listed companies. Boosted by outstanding results, these potential growth companies are
Mesoblast Limited (ASX: MSB)
Mesoblast Limited (ASX: MSB) announced a significant update on December 3, 2024, revealing that its allogeneic cell therapy, Revascor® (rexlemestrocel-L), has demonstrated positive results in improving survival rates and reducing major health complications for patients with high-risk ischemic heart failure (HF) and inflammation. The findings, published in the European Journal of Heart Failure, show that a single intramyocardial injection of Mesoblast’s cell therapy significantly lowered cardiovascular mortality in patients suffering from chronic heart failure with reduced ejection fraction (HFrEF), particularly those with ischemic origins and elevated inflammation markers.
The results of the DREAM-HF trial showed that inflammation and heart problems caused by reduced blood flow (ischemia) were important factors in predicting cardiovascular death in patients who were not treated with the new therapy. Patients with higher levels of inflammation, indicated by markers like high-sensitivity C-reactive protein (hsCRP) in their blood, were at the highest risk. In this study, patients receiving the mesenchymal precursor cell therapy (MPCs) saw an 80% reduction in cardiovascular mortality risk in patients with inflammation, with even larger improvements in outcomes for patients with ischemic HFrEF. Moreover, there was a significant incidence reduction of MACE-related conditions, including heart attack and stroke, which validates the therapy as effective, particularly in the high-risk patient population.
Mesoblast is among the top growth stocks, advancing the approval process for Revascor® in various patient populations, including those with ischemic HFrEF and pediatric heart disease. The company recently received positive feedback from the U.S. FDA regarding an accelerated approval pathway for Revascor® in end-stage ischemic HFrEF patients with a left ventricular assist device (LVAD). Mesoblast's CEO emphasized the company's commitment to bringing innovative cellular therapies to market, and the company’s strong intellectual property position, including U.S. patents related to mesenchymal precursor cells, provides a competitive advantage in treating serious inflammatory diseases.
Orthocell Limited (ASX: OCC)
Orthocell Limited is one of the best growth stocks to buy now having reached a pivotal milestone with the successful completion of its U.S. FDA 510(k) regulatory study for its biological medical device, Remplir™, designed for surgical peripheral nerve repair. The study met all endpoints, providing robust safety and efficacy data to support its 510(k) submission, which remains on track for December CY24. FDA clearance is anticipated in Q1 CY25, enabling commercial distribution in the U.S., the world’s largest healthcare market valued at approximately US$1.6 billion for peripheral nerve repair. The company is also accelerating its international expansion. Orthocell has secured an exclusive distribution agreement with Device Technologies for Remplir™ in Singapore, with commercial launch and initial sales expected in Q1 CY25. Singapore is a strategic gateway to the broader ASEAN region, part of a global nerve repair market projected to exceed US$3.5 billion. Orthocell’s success in Australia and New Zealand further underscores its ability to penetrate sophisticated markets effectively.
Orthocell remains well-capitalized, with $33 million in cash as of October 31, 2024, and no debt. This financial strength, bolstered by a recent $17 million capital raise managed by Canaccord Genuity, positions the company to fund its U.S. launch, scale up manufacturing, and drive its regulatory initiatives across Canada, the EU, the U.K., and Southeast Asia. These efforts are underpinned by robust financial performance, including FY24 revenue growth of 30.8% year-on-year and record Q1 FY25 results, signaling strong momentum. Remplir™, along with Orthocell’s Striate+™, represents a compelling portfolio of innovative products poised to address critical unmet needs in global nerve repair. Initial U.S. market entry, alongside the strategic Singapore launch, reflects Orthocell’s focused commercialization strategy. The company’s ability to rapidly progress from regulatory approvals to market entry demonstrates operational excellence and positions it as a leader in the multi-billion-dollar nerve repair market. With a proven track record, strong balance sheet, and expanding global footprint, Orthocell is strategically positioned to drive sustained growth, deliver long-term shareholder value, and redefine the standard of care in nerve repair.
Source: Company’s Report
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.